Suchergebnisse - "Subbiah, Vivek"

PubPharm (568)

51

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

52

Rare disease research powered by empowered patients : solving the zebra puzzle through social media

enthalten in: Cancer | 2023

von Morgan, G. | Subbiah, V.

53

Direct-to-Patient Clinical Trials : One Small Step or a Giant Leap?

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Desai, A. | Subbiah, V.

CommentIn: Clin Cancer Res. 2023 Jul 5;29(13):2445-2455. - PMID 36862133

54

The emerging role of PI3K inhibitors for solid tumour treatment and beyond

enthalten in: British journal of cancer | 2023

von Belli, C. | Repetto, M. | Anand, S. | +3

55

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

56

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

57

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

enthalten in: Cancer chemotherapy and pharmacology | 2023

von Piha-Paul, S. | Tseng, C. | Tran, H. | +13

58

Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer : Genomics Is the Diagnosis

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Subbiah, V. | Kurzrock, R.

CommentIn: J Clin Oncol. 2023 Aug 20;41(24):4057-4058. - PMID 37311151

59

Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care : an international mixed-method study

enthalten in: BMC medical education | 2023

von Lazure, P. | Sireci, A. | Subbiah, V. | +6

60

Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study

enthalten in: BMC medical education | 2023

von Lazure, P. | Sireci, A. | Subbiah, V. | +6